Innoviva (NASDAQ:INVA) Posts Quarterly Earnings Results

Innoviva (NASDAQ:INVA) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.57 earnings per share for the quarter, Zacks reports. Innoviva had a return on equity of 20.84% and a net margin of 18.31%.

Innoviva Price Performance

INVA traded down $0.13 during trading hours on Wednesday, hitting $17.90. The company’s stock had a trading volume of 553,635 shares, compared to its average volume of 526,492. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 25.94 and a beta of 0.55. The business’s 50-day moving average price is $18.04 and its 200-day moving average price is $18.86. The company has a current ratio of 1.79, a quick ratio of 1.64 and a debt-to-equity ratio of 0.38. Innoviva has a 12 month low of $14.32 and a 12 month high of $21.28.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Innoviva from a “buy” rating to a “hold” rating in a research note on Saturday.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.